Brit10 Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-12-2024
- Paid Up Capital ₹ 0.10 M
as on 29-12-2024
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Revenue %
(FY 2020)
- Profit 38.04%
(FY 2020)
- Ebitda 39.68%
(FY 2020)
- Net Worth -8.93%
(FY 2020)
- Total Assets -2.93%
(FY 2020)
About Brit10 Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Madan Lal and Sanjay Kumawat serve as directors at the Company.
- CIN/LLPIN
U33300RJ2018PTC061110
- Company No.
061110
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2018
- Date of AGM
30 Sep 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Brit10 Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madan Lal  | Director | 04-May-2018 | Current |
| Sanjay Kumawat | Director | 04-May-2018 | Current |
Financial Performance of Brit10 Pharmaceuticals.
Brit10 Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 38.04% increase in profit. The company's net worth dipped by a decrease of 8.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brit10 Pharmaceuticals?
In 2020, Brit10 Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maharshi Badri Pharmaceuticals Private LimitedActive 17 years 8 monthsMadan Lal and Sanjay Kumawat are mutual person
Ramam Organics Private LimitedActive 6 years 8 monthsMadan Lal and Sanjay Kumawat are mutual person
- Scrapking Dotcom Private LimitedActive 6 years 8 months
Madan Lal and Sanjay Kumawat are mutual person
- Janak Bhoomi Builders Private LimitedActive 4 years 1 month
Madan Lal and Sanjay Kumawat are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brit10 Pharmaceuticals?
Unlock and access historical data on people associated with Brit10 Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brit10 Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brit10 Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
